Oncology Town Hall: Updates From Berlin: Oral SERDs in HR+/HER2– Metastatic Breast Cancer — What the Latest Data Really Tell Us

In this podcast, experts Hope S. Rugo, MD, FASCO; Fabrice André, MD, PhD; Nadia Harbeck, MD; and Heather McArthur, MD, MPH; discuss updates from the SERENA-6, evERA, PREcoopERA, and TRAK-ER trials of oral selective estrogen receptor degraders (SERDS) in patients with hormone receptor–positive/HER2-negative (HR+/HER2–) early, advanced, and metastatic breast cancer (MBC). These results were presented at European Society for Molecular Oncology (ESMO) Breast 2026.